Sfoglia per AUTORE
GRIMALDI LM
Collezione ASL Cuneo 1
Items : 2
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. in Journal of neurology / J Neurol. 2022 Feb;269(2):933-944. doi: 10.1007/s00415-021-10676-6. Epub 2021 Jun 28.
2022
ASL Cuneo 1
AOU San Luigi di Orbassano
ASL Cuneo 1
AOU San Luigi di Orbassano
Bellantonio P; Totaro R; Vianello M; Cavalla P; Granella F; Di Sapio A; Bertolotto A; Maimone D; Bergamaschi R; Lus G; Solaro C; Amato MP; Rovaris M; Gasperini C; Ferrò MT; Pesci I; Aguglia U; Maniscalco GT; Sola P; Conte A; De Luca G; Cottone S; Salemi G; Lugaresi A; Inglese M; Bonavita S; Grimaldi LM; Marfia GA; Brescia Morra V; et alii...
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. in Journal of neurology, neurosurgery, and psychiatry / J Neurol Neurosurg Psychiatry. 2020 Dec;91(12):1297-1303. doi: 10.1136/jnnp-2020-323472. Epub 2020 O
2020
ASL Cuneo 1
ASL Cuneo 1
Chisari CG; Grimaldi LM; Salemi G; Ragonese P; Iaffaldano P; Bonavita S; Sparaco M; Rovaris M; D'Arma A; Lugaresi A; Ferrò MT; Grossi P; Di Sapio A; Cocco E; Granella F; Curti E; Lepore V; Trojano M; Patti F;